Skip to main content
. 2017 Dec 17;9(4):4451–4460. doi: 10.18632/oncotarget.23377

Figure 3. Differentiation between PDAC patients and healthy controls using serum miRNAs.

Figure 3

(A) The levels of CA 19–9 and CEA in serum were higher in PDAC patients compared to controls (271.3 vs. 10.5 U/mL, P < 0.0001 and 3.1 vs. 2.0 ng/mL, P = 0.006, respectively). Serum mir-let-7d expression was lower in PDAC patients compared to controls (4.5 vs. 10.3 copies/μL, P < 0.001). (B–D) ROC analysis demonstrated that these three markers could discriminate between PDAC patients and controls with an AUC of 0.68 for CEA (95% CI: 0.56 to 0.79), 0.78 for CA 19-9 (95% CI: 0.66 to 0.89), and 0.83 for mir-let-7d (95% CI: 0.74 to 0.91).